secwatch.observer — SEC 8-K summary
======================================

Issuer:     biote Corp. (BTMD)
CIK:        0001819253
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001193125-23-272557
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biote Q3 revenue $45.6M (+8.5% YoY); net income $19.6M; Adj. EBITDA $14.0M
--------------------------------------------------------------------------

- Revenue $45.6M (+8.5% YoY) driven by procedure revenue growth of 7.4% and supplement growth of 5.1%.
- Net income $19.6M (43.1% margin) vs $0.5M in prior year; basic EPS $0.25 vs $0.00.
- Adjusted EBITDA $14.0M (+14.7% YoY); margin 30.8% (+165bps).
- Reiterated FY2023 guidance: revenue $190-200M, Adj. EBITDA $56-60M; expects lower end.
- Progress in commercial trials of complementary wellness therapeutics (sexual health, weight loss, preventive).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819253/000119312523272557/0001193125-23-272557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819253/000119312523272557/d908833d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-272557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer